MENU
WHWK
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Whitehawk Therapeutics (WHWK) Earnings Date & Reports

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments... Show more

A.I. Advisor
published Earnings

WHWK is expected to report earnings to fall 11.26% to -20 cents per share on March 18

Whitehawk Therapeutics WHWK Stock Earnings Reports
Q4'26
Est.
$-0.20
Q3'26
Beat
by $0.01
Q2'26
Beat
by $0.11
Q1'26
Missed
by $0.29
Q4'25
Beat
by $0.35
The last earnings report on November 09 showed earnings per share of -23 cents, beating the estimate of -23 cents. With 229.09K shares outstanding, the current market capitalization sits at 178.44M.
A.I.Advisor
Nov 06, 2026

Whitehawk Therapeutics (WHWK) Earnings Preview: Pipeline Milestones and Cash Runway in Focus

Key Takeaways

  • Whitehawk Therapeutics (WHWK) is expected to report its third-quarter 2026 results on or around November 11, 2026, before the market open, covering the quarter ended September 30, 2026.
  • Consensus estimates point to a net loss of roughly $0.22 to $0.30 per share, with essentially zero product revenue after the divestiture of its FYARRO business.
  • Investor attention will center on the company's cash runway and progress toward the Phase 1 trial of its lead next-generation antibody-drug conjugate (ADC) candidate, HWK-206.
  • In its most recent quarter, Whitehawk posted a narrower-than-expected loss, a trend shareholders will be watching for again in this report.
  • For more detail on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
  • Explore Trending AI Robots to discover AI-driven trading strategies and market signals.

Earnings Context and Why It Matters

Whitehawk Therapeutics is a clinical-stage oncology company that has undergone a sharp strategic pivot over the past year. After divesting its only commercial product, FYARRO, to KAKEN Pharmaceutical, the company now generates essentially no product revenue and is focused entirely on advancing a portfolio of next-generation ADCs. Because the income statement no longer reflects meaningful sales, this quarterly report matters less for top-line results and more for operating discipline, cash management, and research and development (R&D) progress. For investors, the print is a key checkpoint on whether Whitehawk remains on track to reach meaningful clinical milestones while preserving a cash runway that management has guided into the second half of 2028.

Earnings Expectations

Heading into the report, Wall Street consensus calls for Whitehawk Therapeutics to post a net loss of roughly $0.22 to $0.30 per share for the third quarter of fiscal 2026. Revenue is expected to be negligible, reflecting the completed sale of the FYARRO franchise. With no commercial product to drive sales, analysts and investors will instead focus on operating expenses, particularly R&D spending, and on the balance of cash and cash equivalents at quarter end.

For historical context, the company reported a loss of $0.20 per share in the second quarter of 2026, a narrower deficit than the roughly $0.31 per share analysts had projected. In the first quarter, it reported a loss of $0.32 per share against a $0.33 consensus estimate. Key metrics to watch this quarter include total operating loss, R&D expense, cash position, and any updated guidance on how long the company's liquidity can fund its development programs.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like WHWK, it offers a structured way to surface actionable ideas across the broader market.

Market Reaction and Investor Sentiment

Sentiment heading into the report remains cautious. Despite beating consensus estimates in its last release, the stock has drifted lower in the weeks since, with data indicating a negative post-earnings drift following the August announcement. As a pre-revenue clinical-stage company, Whitehawk is highly sensitive to news flow around its pipeline and balance sheet, and the market's focus has shifted toward whether the company can execute on its ADC programs without dilutive financing in the near term. Key risk factors heading into earnings include the pace of R&D spending, any changes to cash-runway guidance, and the timing of the planned Phase 1 trial initiation for HWK-206.

Forward Outlook and Key Factors to Monitor

Following the earnings release, investors will be watching several forward-looking factors closely. The most important near-term catalyst is the initiation of the Phase 1 clinical trial for HWK-206, the company's lead next-generation ADC candidate, which management has indicated is expected to begin during the third quarter of 2026.

Cash management will remain a central theme. After a roughly $87.5 million financing completed in May 2026 lifted cash reserves to about $190 million and extended the operating runway into the second half of 2028, investors will look for confirmation that spending remains aligned with that trajectory. Any meaningful acceleration in R&D or general and administrative expenses could pressure sentiment around the company's funding needs.

Broader industry dynamics also matter. The ADC space continues to attract strong interest from both large pharmaceutical companies and investors, and progress across Whitehawk's three next-generation ADC programs could shape how the market values the pipeline. Finally, investors should monitor any commentary on potential partnerships, additional financing, or strategic updates that management provides alongside the results, as these disclosures often carry more weight than the headline financial figures for a pre-revenue biotech.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company

Industry Biotechnology

Industry
Pharmaceuticals Major
Address
2 Headquarters Plaza East Building
Phone
+1 551 321-2234
Employees
23
Web
https://www.whitehawktx.com